Drugs / NP41
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05043519 | Jan 2022 → Aug 2023 | nervous system injury | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP41 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05043519 ↗ |
| Modality | Peptide | “NP41 is a novel nerve-binding peptide” NCT05043519 ↗ |
| Route | Intravenous | “The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.” NCT05043519 ↗ |